Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNA7 | P36544 | 1/20 | 0.64 |
| ▸ | POLB | P06746 | 1/20 | 0.58 |
| ▸ | FFAR1 | O14842 | 13/20 | 0.58 |
| ▸ | FFAR4 | Q5NUL3 | 11/20 | 0.58 |
| ▸ | RXRG | P48443 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28799269 | 0.88 | CHRNA7 (0.55) | CHRNA7POLBFFAR1FFAR4 | |
| SCHEMBL490491 | 0.85 | POLB (0.67) | POLB | |
| SCHEMBL29998634 | 0.85 | POLB (0.67) | POLB | |
| SCHEMBL28057532 | 0.84 | CHRNA7 (0.62) | CHRNA7POLBFFAR1FFAR4 | |
| SCHEMBL1404941 | 0.84 | CHRNA7 (0.62) | CHRNA7POLBFFAR1FFAR4 | |
| SCHEMBL2397247 | 0.83 | FFAR1 (0.59) | POLBFFAR1FFAR4RXRG | |
| SCHEMBL30637597 | 0.83 | FFAR1 (0.59) | POLBFFAR1FFAR4RXRG | |
| Hydrochloric Acid SCHEMBL30461911 | 0.81 | FFAR1 (0.58) | POLBFFAR1FFAR4 | |
| SCHEMBL1142805 | 0.81 | CAMK2A (0.51) | CHRNA7 | |
| SCHEMBL30523650 | 0.81 | CAMK2A (0.51) | CHRNA7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240067665-A1 | SMALL MOLECULES FOR BORON NEUTRON CAPTURE THERAPY | AVIKO RADIOPHARMACEUTICALS LLC (US) | 2024-02-29 | — | — | US | disclosed |
| EP-2595952-A1 | AGONISTS OF GPR40 | Connexios Life Sciences Pvt. Ltd. (IN) | 2013-05-29 | — | — | EP | disclosed |
| WO-2012011125-A1 | AGONISTS OF GPR40 | CONNEXIOS LIFE SCIENCES PVT. LTD. (IN) | 2012-01-26 | — | — | WO | disclosed |
| WO-2007008603-A1 | MONOMETHYLVALINE COMPOUNDS HAVING PHENYLALANINE SIDE-CHAIN MODIFICATIONS AT THE C-TERMINUS | SEATTLE GENETICS, INC. (US) | 2007-01-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240067665-A1 | SMALL MOLECULES FOR BORON NEUTRON CAPTURE THERAPY | NME2, BTD, BLVRB | CHRNA7 3214/4885POLB 198/4885FFAR1 3549/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.